Applications of CRISPR Technology in Drug Discovery

Session Chair - Not Funded(s)

• 

  Ceri Wiggins, PhD (she/her/hers)

  Director
  AstraZeneca, England, United Kingdom

Session Chair(s)

• JD

  John Doench, PhD

  Director R&D
  Broad Institute, Massachusetts, United States

Presentations:

• 1:00 PM – 1:30 PM

  Base editing screens to define drug-target interactions
  

  John G. Doench, PhD – Broad Institute
• 1:30 PM – 2:00 PM

  Next-Generation Pooled and Arrayed CRISPR-Cas9 screens to identify and prioritise drug targets
  

  Divya Malik, PhD – Horizon Discovery Ltd (PerkinElmer)
• 2:00 PM – 2:30 PM

  Identification of novel targets for inhibition of cellular senescence in Idiopathic Pulmonary Fibrosis
  

  Jenna M. Bradley, PhD – Astrazeneca